Article
Voriconazole therapy and CYP2C19 phenotype: identifying patients who may need alternative antifungal therapy.
The Journal of antimicrobial chemotherapy - 5 May 2026
Wehbe Eman, Sreeharan Thulashigan, Sutrave Gaurav, Bui Jessica, Lau Cindy, Park Jung Yeun, Sandaradura Indy, Darley David, Macdonald Peter, Milliken Samuel, Fung Jiin Nyuk, Jones Graham, Kizny Gordon Alice, Kliman David, Lu Christine Y, Marriott Deborah, Alffenaar Jan-Willem C, Stocker Sophie L
Abstract excerpt
BACKGROUND AND OBJECTIVES: CYP2C19 phenotype is a known contributor to the interpatient variability in voriconazole response. Alternative therapy is recommended for ultrarapid/rapid and poor metabolizers due to increased probability of subtherapeutic exposure and side effects, respectively. We aimed to evaluate whether CYP2C19 phenotype is associated with switching from voriconazole to alternative antifungal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.